File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy

TitleCholesterol-lowering therapy may retard the progression of diabetic nephropathy
Authors
KeywordsHMG CoA reductase inhibitor
Hypercholesterolaemia
Lipids
Lipoprotein(a)
Lipoproteins
Nephropathy
Non-insulin-dependent diabetes mellitus
Issue Date1995
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00125/index.htm
Citation
Diabetologia, 1995, v. 38 n. 5, p. 604-609 How to Cite?
AbstractThere is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury. We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus. Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin, an HMG CoA reductase inhibitor (n = 16; mean dose 30.0 ± 12.6 mg/day) or placebo (n = 18) for 2 years. Renal function was assessed by serially measuring the serum creatinine, glomerular filtration rate (using Cr51-EDTA), and 24-h urinary protein excretion. Lovastatin treatment was associated with significant reductions in total cholesterol (p < 0.001), LDL-cholesterol (p < 0.001) and apo B (p < 0.01), the reductions at 24 months being 26, 30 and 18%, respectively. Beneficial effects on serum triglyceride, HDL-cholesterol and apo A1 levels were also observed. Lp(a) showed no significant change in both groups. Glomerular filtration rate deteriorated significantly in the placebo group after 24 months (p < 0.025) but showed no significant change in the lovastatin-treated patients. The increase in serum creatinine was statistically significant (p < 0.02) in placebo-treated patients at 12 and 24 months, and in the lovastatin group after 24 months. Twenty-four hour urinary protein excretion increased in both groups (p < 0.05). Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes. We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy.
Persistent Identifierhttp://hdl.handle.net/10722/77280
ISSN
2015 Impact Factor: 6.206
2015 SCImago Journal Rankings: 3.528
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorCheng, IKPen_HK
dc.contributor.authorJanus, EDen_HK
dc.contributor.authorPang, RWCen_HK
dc.date.accessioned2010-09-06T07:30:11Z-
dc.date.available2010-09-06T07:30:11Z-
dc.date.issued1995en_HK
dc.identifier.citationDiabetologia, 1995, v. 38 n. 5, p. 604-609en_HK
dc.identifier.issn0012-186Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/77280-
dc.description.abstractThere is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury. We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus. Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin, an HMG CoA reductase inhibitor (n = 16; mean dose 30.0 ± 12.6 mg/day) or placebo (n = 18) for 2 years. Renal function was assessed by serially measuring the serum creatinine, glomerular filtration rate (using Cr51-EDTA), and 24-h urinary protein excretion. Lovastatin treatment was associated with significant reductions in total cholesterol (p < 0.001), LDL-cholesterol (p < 0.001) and apo B (p < 0.01), the reductions at 24 months being 26, 30 and 18%, respectively. Beneficial effects on serum triglyceride, HDL-cholesterol and apo A1 levels were also observed. Lp(a) showed no significant change in both groups. Glomerular filtration rate deteriorated significantly in the placebo group after 24 months (p < 0.025) but showed no significant change in the lovastatin-treated patients. The increase in serum creatinine was statistically significant (p < 0.02) in placebo-treated patients at 12 and 24 months, and in the lovastatin group after 24 months. Twenty-four hour urinary protein excretion increased in both groups (p < 0.05). Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes. We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy.en_HK
dc.languageengen_HK
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00125/index.htmen_HK
dc.relation.ispartofDiabetologiaen_HK
dc.subjectHMG CoA reductase inhibitoren_HK
dc.subjectHypercholesterolaemiaen_HK
dc.subjectLipidsen_HK
dc.subjectLipoprotein(a)en_HK
dc.subjectLipoproteinsen_HK
dc.subjectNephropathyen_HK
dc.subjectNon-insulin-dependent diabetes mellitusen_HK
dc.subject.meshAnticholesteremic Agents - therapeutic useen_HK
dc.subject.meshApolipoprotein A-I - blooden_HK
dc.subject.meshApolipoproteins - blooden_HK
dc.subject.meshApolipoproteins B - blooden_HK
dc.subject.meshApoprotein(a)en_HK
dc.subject.meshBlood Pressure - drug effectsen_HK
dc.subject.meshBody Mass Indexen_HK
dc.subject.meshCholesterol - blooden_HK
dc.subject.meshCholesterol, HDL - blooden_HK
dc.subject.meshCholesterol, LDL - blooden_HK
dc.subject.meshCreatinine - blooden_HK
dc.subject.meshDiabetes Mellitus, Type 2 - blood - drug therapy - physiopathologyen_HK
dc.subject.meshDiabetic Dieten_HK
dc.subject.meshDiabetic Nephropathies - prevention & controlen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshGlomerular Filtration Rate - drug effectsen_HK
dc.subject.meshHemoglobin A, Glycosylated - analysisen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitorsen_HK
dc.subject.meshLipoprotein(a)en_HK
dc.subject.meshLovastatin - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPlacebosen_HK
dc.subject.meshSingle-Blind Methoden_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTriglycerides - blooden_HK
dc.titleCholesterol-lowering therapy may retard the progression of diabetic nephropathyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0012-186X&volume=38&spage=604&epage=609&date=1995&atitle=Cholesterol-lowering+therapy+may+retard+the+progression+of+diabetic+nephropathyen_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailPang, RWC: robertap@hkucc.hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s001250050326en_HK
dc.identifier.pmid7489845-
dc.identifier.scopuseid_2-s2.0-0028918868en_HK
dc.identifier.hkuros2128en_HK
dc.identifier.volume38en_HK
dc.identifier.issue5en_HK
dc.identifier.spage604en_HK
dc.identifier.epage609en_HK
dc.identifier.isiWOS:A1995QX78600015-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridCheng, IKP=7102537483en_HK
dc.identifier.scopusauthoridJanus, ED=7006936536en_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats